422 related articles for article (PubMed ID: 24810491)
1. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
2. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
[TBL] [Abstract][Full Text] [Related]
4. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis.
Uthman OA; Okwundu C; Gbenga K; Volmink J; Dowdy D; Zumla A; Nachega JB
Ann Intern Med; 2015 Jul; 163(1):32-9. PubMed ID: 26148280
[TBL] [Abstract][Full Text] [Related]
5. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.
Grinsztejn B; Hosseinipour MC; Ribaudo HJ; Swindells S; Eron J; Chen YQ; Wang L; Ou SS; Anderson M; McCauley M; Gamble T; Kumarasamy N; Hakim JG; Kumwenda J; Pilotto JH; Godbole SV; Chariyalertsak S; de Melo MG; Mayer KH; Eshleman SH; Piwowar-Manning E; Makhema J; Mills LA; Panchia R; Sanne I; Gallant J; Hoffman I; Taha TE; Nielsen-Saines K; Celentano D; Essex M; Havlir D; Cohen MS;
Lancet Infect Dis; 2014 Apr; 14(4):281-90. PubMed ID: 24602844
[TBL] [Abstract][Full Text] [Related]
6. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
Cotton MF; Violari A; Otwombe K; Panchia R; Dobbels E; Rabie H; Josipovic D; Liberty A; Lazarus E; Innes S; van Rensburg AJ; Pelser W; Truter H; Madhi SA; Handelsman E; Jean-Philippe P; McIntyre JA; Gibb DM; Babiker AG;
Lancet; 2013 Nov; 382(9904):1555-63. PubMed ID: 24209829
[TBL] [Abstract][Full Text] [Related]
7. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
[TBL] [Abstract][Full Text] [Related]
9. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
[TBL] [Abstract][Full Text] [Related]
10. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
11. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
Molina JM; Grund B; Gordin F; Williams I; Schechter M; Losso M; Law M; Ekong E; Mwelase N; Skoutelis A; Wiselka MJ; Vandekerckhove L; Benfield T; Munroe D; Lundgren JD; Neaton JD;
Lancet HIV; 2018 Apr; 5(4):e172-e180. PubMed ID: 29352723
[TBL] [Abstract][Full Text] [Related]
12. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
[TBL] [Abstract][Full Text] [Related]
13. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.
BREATHER (PENTA 16) Trial Group
Lancet HIV; 2016 Sep; 3(9):e421-e430. PubMed ID: 27562743
[TBL] [Abstract][Full Text] [Related]
14. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old.
Siegfried N; Davies MA; Penazzato M; Muhe LM; Egger M
Cochrane Database Syst Rev; 2013 Oct; 10(10):CD010309. PubMed ID: 24114324
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
Nanteza MW; Mayanja-Kizza H; Charlebois E; Srikantiah P; Lin R; Mupere E; Mugyenyi P; Boom WH; Mugerwa RD; Havlir DV; Whalen CC
J Infect Dis; 2011 Sep; 204(6):884-92. PubMed ID: 21849285
[TBL] [Abstract][Full Text] [Related]
16. Association of CD4 T cell count and optimal timing of antiretroviral therapy initiation with immune reconstitution inflammatory syndrome and all-cause mortality for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis.
Li L; Li J; Chai C; Liu T; Li P; Qu M; Zhao H
Int J Clin Exp Pathol; 2021; 14(6):670-679. PubMed ID: 34239668
[TBL] [Abstract][Full Text] [Related]
17. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
[TBL] [Abstract][Full Text] [Related]
18. Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.
Ravimohan S; Tamuhla N; Steenhoff AP; Letlhogile R; Nfanyana K; Bellamy SL; MacGregor RR; Gross R; Weissman D; Bisson GP
Lancet Infect Dis; 2015 Apr; 15(4):429-38. PubMed ID: 25672566
[TBL] [Abstract][Full Text] [Related]
19. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.
Mfinanga S; Chanda D; Kivuyo SL; Guinness L; Bottomley C; Simms V; Chijoka C; Masasi A; Kimaro G; Ngowi B; Kahwa A; Mwaba P; Harrison TS; Egwaga S; Jaffar S;
Lancet; 2015 May; 385(9983):2173-82. PubMed ID: 25765698
[TBL] [Abstract][Full Text] [Related]
20. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
Kityo C; Szubert AJ; Siika A; Heyderman R; Bwakura-Dangarembizi M; Lugemwa A; Mwaringa S; Griffiths A; Nkanya I; Kabahenda S; Wachira S; Musoro G; Rajapakse C; Etyang T; Abach J; Spyer MJ; Wavamunno P; Nyondo-Mipando L; Chidziva E; Nathoo K; Klein N; Hakim J; Gibb DM; Walker AS; Pett SL;
PLoS Med; 2018 Dec; 15(12):e1002706. PubMed ID: 30513108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
